BYSI BeyondSpring, Inc. Expected Profit

Corporate company logo of BeyondSpring Inc (BYSI)

BeyondSpring Inc. (BYSI) is expanding the presence of Plinabulin in neutropenia therapy, developing its small molecule portfolio. The forward earnings metric allows for an assessment of the business's fundamental boundaries, with the indicator currently standing at 0.01. Demand for reducing chemotherapy side effects is driving the search for global partners. The implementation of AI is accelerating drug design, although clinical trials remain the responsibility of physicians.

BYSI - BeyondSpring Inc. Expected Net Income over the range 09/25/2023 - 10/24/2023

Analytical breakdowns for BeyondSpring, Inc. (BYSI)

- share price and consensus valuation forecast:
Stock Price BeyondSpring Inc.|BYSI - Analyst Consensus Forecast
- market capitalization data:
Market Value BeyondSpring|BYSI - Total Company Value
- company book value details:
Accounting Value per Share BeyondSpring|BYSI - Accounting Value of Company|Market Value to Book Value Ratio beyondspringpharma.com|BYSI - Company Assets
- debt and solvency information:
Debt to Equity BeyondSpring Inc.|BYSI - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital BeyondSpring Pharma|BYSI - Company Total Debt|Debt to Book Capitalization Ratio BeyondSpring|BYSI - Long-Term Debt|Company Short-Term Debt BeyondSpring|Quick Liquidity beyondspringpharma.com
- earnings and market ratios statistics:
BYSI - Company Net Income|Projected Future Earnings BeyondSpring Inc.|BYSI - Market Cap to Net Income Ratio|Projected Price to Earnings BeyondSpring|BYSI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio BeyondSpring|BYSI - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months BeyondSpring|BYSI - Earnings per share for the last four quarters|Quarterly EPS earnings growth beyondspringpharma.com|BYSI - Earnings per share increase in current year|Earnings growth forecast for next year BeyondSpring Inc.
Comprehensive company analysis:BYSI, BeyondSpring Inc.
Core merchandise of BeyondSpring, Inc.

The profit scale forecast for BeyondSpring Inc. (BYSI) directly reflects the probability of regulatory approval for new oncology drugs. This indicator aggregates expected net income based on current market conditions and clinical trial stages. The calculation is based on the discounting of future cash flows, accounting for financing and competition risks. The upward trend of the curve confirms the resilience of the business model, although inflated expectations may signal an overvaluation of the asset.

Competitors of BeyondSpring Inc.

INCY (Incyte Corporation) - Projected Future Earnings|Projected Future Earnings hutch-med.com|Expected Profit Nuvation Bio (NUVB)|Expected Profit DAWN (Day One Biopharmaceuticals, Inc.)|Monopar Pharma - Future Profit|Expected Net Income INBX|IMAB - Expected Profit|Expected Net Profit fennecpharma.com|herontx.com (HRTX) - Expected Profit|Net Profit Forecast NVCT|CHRS (Coherus Biosciences) - Projected Future Earnings|Future Profit Corbus Pharmaceuticals, Inc. (CRBP)|Expected Profit Cardiff Oncology, Inc. (CRDF)|BCAB - Expected Net Profit|Expected Profit Lixte Biotechnology Holdings, Inc. LIXT|Citius Pharmaceuticals Inc. - Expected Profit|CLRB - Expected Profit|Expected Net Profit BioLineRx Corporation|CANF: Projected Future Earnings|Projected Net Profit Aprea Therapeutics, Inc. APRE|Future Profit KZIA|Expected Net Profit Silexion SLXN|Future Profit NCNA (NuCana plc)|CMRX (Chimerix Inc) - Expected Net Income|Cyclacel Pharmaceuticals - Future Profit|Future Net Profit GTHX (G1 Therapeutics Inc.)|Kronos Bio - Projected Future Earnings|Expected Net Income KTRA (Kintara Therapeutics Inc)|ONCT: Projected Future Earnings|Expected Net Profit Portage Biotech Corp (PRTG)